How to cite item

Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and nonsquamous subtypes of non-small cell lung cancer

   
@article{JTD24032,
	author = {Masaru Katoh},
	title = {Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and nonsquamous subtypes of non-small cell lung cancer},
	journal = {Journal of Thoracic Disease},
	volume = {10},
	number = {9},
	year = {2018},
	keywords = {},
	abstract = {Immuno-oncology drugs that inhibit immunosuppressive receptors (CTLA4, LAG3, PD-1, TIGIT and TIM3) or activate immunostimulatory receptors (4-1BB, GITR, ICOS and OX40) are emerging as promising therapeutics for cancer patients (1-3). PD-1 (CD279 or PDCD1), consisting of the extracellular N-terminal loop and immunoglobulin variable (IgV) domain, a single transmembrane domain and intracellular ITIM and ITSM motifs, is a representative target of immuno-oncology therapy (4-6).},
	issn = {2077-6624},	url = {https://jtd.amegroups.org/article/view/24032}
}